ES2109362T3 - Unas proteinas administrables oralmente y metodo para hacerlas. - Google Patents

Unas proteinas administrables oralmente y metodo para hacerlas.

Info

Publication number
ES2109362T3
ES2109362T3 ES92914240T ES92914240T ES2109362T3 ES 2109362 T3 ES2109362 T3 ES 2109362T3 ES 92914240 T ES92914240 T ES 92914240T ES 92914240 T ES92914240 T ES 92914240T ES 2109362 T3 ES2109362 T3 ES 2109362T3
Authority
ES
Spain
Prior art keywords
protein
therapeutic protein
stabilizing agent
administrable
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92914240T
Other languages
English (en)
Inventor
Jacob G Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Application granted granted Critical
Publication of ES2109362T3 publication Critical patent/ES2109362T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTA UNA PROTEINA TERAPEUTICA QUE SE PUEDE ADMINISTRAR POR VIA ORAL A BASE DE COMBINAR LA PROTEINA TERAPEUTICA CON UN AGENTE ESTABILIZADOR EN UNA SOLUCION ACUOSA. SE REVISTE UNA PILDORA DE AZUCAR CON LA SOLUCION Y SE MICROENCAPSULA CON UNA COMPOSICION DE REVESTIMIENTO ENTERICA EMULSIONABLE EN AGUA. LAS MICROCAPSULAS SE ADMINISTRAN POR VIA ORAL. EL REVESTIMIENTO PROTEGE A LA PROTEINA A MEDIDA QUE ESTA PASA A TRAVES DEL ESTOMAGO. AL ALCANZAR LOS INTESTINOS DELGADOS, EL PH BASICO DE LOS JUGOS INTESTINALES DISOLVERA EL REVESTIMIENTO PERMITIENDO ASI LA LIBERACION DE LA PROTEINA. EL AGENTE ESTABILIZADOR PROTEGERA A LA PROTEINA TERAPEUTICA DURANTE EL PROCESO DE ENCAPSULACION E INHIBIRA LAS ENZIMAS PROTEOLITICAS DE LOS INTESTINOS DELGADOS LO QUE PERMITIRA QUE AL PROTEINA TERAPEUTICA ALCANCE EL TEJIDO LINFOIDE DE LOS INTESTINOS DELGADOS.
ES92914240T 1991-06-21 1992-06-11 Unas proteinas administrables oralmente y metodo para hacerlas. Expired - Lifetime ES2109362T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71916091A 1991-06-21 1991-06-21

Publications (1)

Publication Number Publication Date
ES2109362T3 true ES2109362T3 (es) 1998-01-16

Family

ID=24888975

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92914240T Expired - Lifetime ES2109362T3 (es) 1991-06-21 1992-06-11 Unas proteinas administrables oralmente y metodo para hacerlas.

Country Status (11)

Country Link
US (4) US5609871A (es)
EP (1) EP0590060B1 (es)
JP (1) JPH06508371A (es)
AT (1) ATE158180T1 (es)
AU (1) AU664561B2 (es)
CA (1) CA2110899C (es)
DE (1) DE69222306T2 (es)
DK (1) DK0590060T3 (es)
ES (1) ES2109362T3 (es)
GR (1) GR3025628T3 (es)
WO (1) WO1993000077A1 (es)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
AU664561B2 (en) * 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
US6083503A (en) * 1991-08-28 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
DK0603992T4 (da) † 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5551058A (en) * 1994-10-31 1996-08-27 Motorola, Inc. Method and system for intelligent cell selection using location data in cellular systems
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
US6605276B1 (en) 1995-05-09 2003-08-12 University Of Medicine & Dentistry Of New Jersey Treatment of ulcerative colitis with tropomyosin isoforms and monoclonal antibodies to tropomyosin isoforms
US5789014A (en) * 1995-12-25 1998-08-04 Shin-Etsu Chemical Co., Ltd. Method of manufacturing a solid preparation coated with non-solvent coating
JP2000509146A (ja) * 1996-04-12 2000-07-18 オンコール，インコーポレーテッド 遅延クエンチングによりホルムアルデヒド固定を制御する方法および組成物
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6328967B1 (en) * 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
DE19854749A1 (de) * 1998-11-27 2000-05-31 Privates Inst Bioserv Gmbh Verwendung von Kapseln, die eine oder mehrere antigene Substanzen enthalten, zur Prävention und/oder Behandlung von Autoimmunerkrankungen
IL143441A0 (en) * 1998-11-30 2002-04-21 Cytos Biotechnology Ag Non-naturally occuring antigen arrays and processes for the preparation thereof
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
DE10044129A1 (de) * 1999-09-07 2001-05-17 Bioserv Ag Neue Autovakzinen zur Erzeilung einer Immuntoleranz
US6500462B1 (en) * 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
CA2396237A1 (en) * 2000-01-07 2001-07-19 Jacob Gabriel Michael Selective activation of a th1 or th2 lymphocyte regulated immune response
KR100753765B1 (ko) * 2000-02-08 2007-08-31 알레간 인코포레이티드 보툴리눔 독소 약제학적 조성물
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP1335938B1 (en) 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
US6932861B2 (en) * 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US20060040899A1 (en) * 2000-12-15 2006-02-23 Hassan Jomaa Medicaments containing bisphosphonic acids and derivatives thereof for preventing and treating diseases and allergies
CA2449175A1 (en) * 2001-06-05 2002-12-12 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20030083286A1 (en) * 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
WO2003028668A2 (en) * 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
SK1732004A3 (sk) * 2001-10-15 2005-06-02 R�Hm Gmbh & Co. Kg Použitie kopolyméru na prípravu liekovej formy, ktorá ako účinnú látku obsahuje peptid alebo proteín
AU2003273182B8 (en) 2002-05-10 2009-05-07 Agennix Incorporated Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
US20040043070A1 (en) * 2002-05-14 2004-03-04 Ayres James W. Hot melt coating by direct blending and coated substrates
DE60336063D1 (de) * 2002-05-31 2011-03-31 Childrens Hosp Medical Center Verfahren, zusammensetzung und kit für die antigenbindung von norwalk-ähnlichen viren
US7977098B2 (en) 2002-05-31 2011-07-12 Children's Hospital Medical Center Antigenic binding patterns of norovirus to human histo-blood group antigens
EP1545587B1 (en) 2002-09-16 2011-02-09 Agennix Incorporated Lactoferrin compositions and methods of diabetic ulcer treatment
ES2641525T3 (es) 2002-10-16 2017-11-10 Purdue Pharma L.P. Anticuerpos que se unen a CA 125/0722P asociado a células y métodos de uso de los mismos
EP2267032A3 (en) 2002-11-08 2011-11-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
RU2357974C2 (ru) 2003-01-10 2009-06-10 Аблинкс Н.В. Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами
PL1615646T5 (pl) 2003-04-08 2022-12-19 Progenics Pharmaceuticals, Inc. Preparaty farmaceutyczne zawierające metylonaltrekson
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
EP1617846A1 (en) * 2003-04-08 2006-01-25 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
US20070141071A1 (en) * 2003-05-14 2007-06-21 Oregon State University Hot melt coating by direct blending and coated substrates
JP5021309B2 (ja) 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
WO2006036278A2 (en) 2004-09-18 2006-04-06 University Of Maryland, Baltimore THERAPEUTIC AGENTS TARGETING THE NCCa-ATP CHANNEL AND METHODS OF USE THEREOF
BRPI0518151A2 (pt) * 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
US20060205753A1 (en) * 2005-01-20 2006-09-14 Israel Robert J Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
BRPI0608818A2 (pt) * 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
WO2006099175A2 (en) * 2005-03-11 2006-09-21 Euro-Celtique S.A. Compositions comprising an anti-ca125 antibody and a cytotoxic compound and their use for the treatment of cancer
CA2605652C (en) 2005-04-22 2016-05-24 Universite De Geneve Polylactide compositions and uses thereof
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
ES2379283T3 (es) 2005-05-18 2012-04-24 Ablynx N.V. Proteínas de unión a albúmina sérica
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
CN101505781A (zh) 2006-06-22 2009-08-12 阿根尼克斯有限公司 作为辐射防护物质的乳铁蛋白
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US20110152263A1 (en) * 2006-11-16 2011-06-23 Xi Jiang Composition and method for inhibiting norovirus infection
EP2111224B1 (en) 2007-01-12 2016-07-13 University of Maryland, Baltimore Targeting ncca-atp channel for organ protection following ischemic episode
US8207196B2 (en) 2007-02-02 2012-06-26 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
HUE025662T2 (en) 2007-03-29 2016-04-28 Wyeth Llc Peripheral opioid receptor and antagonists and their uses
EP2137191B8 (en) * 2007-03-29 2016-06-08 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
JP2010522756A (ja) 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
EP3409687A1 (en) 2007-06-01 2018-12-05 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
JP5322405B2 (ja) * 2007-06-07 2013-10-23 小林製薬株式会社 タンパク質含有組成物
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
EP2240489A1 (en) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
US8685995B2 (en) * 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5985824B2 (ja) 2008-07-01 2016-09-06 ザ ユニヴァーシティー オヴ シカゴ オピオイド受容体アンタゴニスト含有の粒子および使用方法
US20110263478A1 (en) 2008-09-16 2011-10-27 Simard J Marc Sur1 inhibitors for therapy
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
EP3141561B1 (en) 2009-04-24 2018-09-12 Vanderbilt University Anti-tgf-beta induction of bone growth
EP2440582B1 (en) 2009-06-09 2018-11-07 Children's Hospital Medical Center Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2011104352A1 (en) 2010-02-25 2011-09-01 Agennix Ag Oral lactoferrin in the treatment of severe sepsis
CA2902942C (en) 2010-07-28 2020-12-22 David S. Block Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
EP3636778B1 (en) 2010-08-18 2022-01-12 Fred Hutchinson Cancer Research Center Agents for use in treating facioscapulohumeral dystrophy (fshd)
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
BR112013006088B1 (pt) 2010-09-15 2022-06-14 Randall J Mrsny Construto de entrega isolado, e, composição farmacêutica
US20130209528A1 (en) 2010-10-18 2013-08-15 Agency For Science, Technology And Research Use of exosomes to promote or enhance hair growth
WO2012070971A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Косметологическая и фармацевтическая композиция для омоложения и восстанов- ления кожи, в том числе после хирургических операций
AU2012287120B2 (en) 2011-07-22 2017-02-23 The University Of Chicago Treatments for migraine and related disorders
WO2013057592A2 (en) 2011-09-14 2013-04-25 King Abdullah University Of Science And Technology Treatment of sickle cell disease
WO2013041969A2 (en) 2011-09-21 2013-03-28 King Abdullah University Of Science And Technology Didemnin biosynthetic gene cluster in tistrella mobilis
AR092821A1 (es) 2012-04-20 2015-05-06 Sucampo Ag Conjugado de derivado de acido graso-polimero
WO2014160339A1 (en) 2013-03-13 2014-10-02 Board Of Regents, The University Of Texas System Compounds for treating inflammatory and hyperproliferative diseases
US9321803B2 (en) 2013-07-12 2016-04-26 Children's Hospital Medical Center Compositions and methods for inhibiting norovirus infection
AU2014357521B2 (en) 2013-12-02 2018-10-11 Baylor College Of Medicine Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
EA033248B1 (ru) * 2014-02-20 2019-09-30 Вэксарт, Инк. Композиция и способ индукции иммунного ответа
JP2017517250A (ja) * 2014-04-28 2017-06-29 シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーＳｉｇｍａ−Ａｌｄｒｉｃｈ Ｃｏ．， ＬＬＣ 標的エンドヌクレアーゼを用いる哺乳類ゲノムのエピジェネティック修飾
BR112016025866A2 (pt) 2014-05-07 2017-12-12 Applied Molecular Transp Llc composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
US10278986B2 (en) 2014-08-14 2019-05-07 The Regents Of The University Of Colorado, A Body Corporate Antibody-siRNA conjugates and uses therefor
CA2958578A1 (en) 2014-08-21 2016-02-25 The General Hospital Corporation Tumor necrosis factor superfamily and tnf-like ligand muteins and methods of preparing and using the same
WO2016061531A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US10302644B2 (en) 2014-11-04 2019-05-28 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating multiple myeloma
KR101708200B1 (ko) 2015-03-24 2017-03-08 아우토리브 디벨롭먼트 아베 차량용 커튼 에어백
HK1250040A1 (zh) 2015-03-31 2018-11-23 Sorriso Pharmaceuticals, Inc. 多肽
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
US11285190B2 (en) 2015-04-20 2022-03-29 The Board Of Regents Of The University Of Texas System CLEC11a is a bone growth agent
JP6912394B2 (ja) 2015-06-12 2021-08-04 バクサート インコーポレイテッド Ｒｓｖおよびノロウイルス抗原の小腸送達のための製剤
WO2016205615A1 (en) 2015-06-17 2016-12-22 The Johns Hopkins University Tdp-43 in degenerative disease
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
HRP20211167T1 (hr) 2015-08-07 2021-10-15 ALX Oncology Inc. Konstrukcije koje imaju sirp-alfa domenu ili njihove varijante
WO2017132321A1 (en) 2016-01-29 2017-08-03 The Johns Hopkins University Novel inhibitors of bacterial growth
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
US11180758B2 (en) 2016-02-24 2021-11-23 The Johns Hopkins University Antiviral proteins and their uses in therapeutic methods
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
WO2017156356A1 (en) 2016-03-10 2017-09-14 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
JP2019510088A (ja) 2016-03-17 2019-04-11 ザ ジョンズ ホプキンス ユニバーシティーＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ Ｐａｒｉｓのファルネシル化によってパーキンソン病を予防または治療する方法
EP3436609B1 (en) 2016-03-30 2022-05-04 The Johns Hopkins University Olfr90 specificity and methods of detection
CA3019482A1 (en) 2016-03-31 2017-10-05 Vhsquared Limited Compositions
WO2017189483A1 (en) 2016-04-25 2017-11-02 The Johns Hopkins University Znt8 assays for drug development and pharmaceutical compositions
US20190389941A1 (en) 2016-07-22 2019-12-26 Gliknik Inc. Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced fc receptor binding
EP3295956A1 (en) 2016-09-20 2018-03-21 Biomay Ag Polypeptide construct comprising fragments of allergens
US11149275B2 (en) 2016-10-10 2021-10-19 The Johns Hopkins University Device and method to treat esophageal disorders
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CA3043261A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
JP2020513810A (ja) 2017-03-14 2020-05-21 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ クロマチンアクセシビリティ及び心筋細胞の再生を誘発する、Ｈｉｐｐｏエフェクターである優性活性Ｙａｐ
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
EP3652540A4 (en) 2017-07-12 2021-04-07 The Johns Hopkins University PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR DIAGNOSIS OF TYPE 1 DIABETES
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
US11246857B2 (en) 2017-12-14 2022-02-15 The Johns Hopkins University Anti-fungal inhibitors
CN112105631A (zh) 2018-03-06 2020-12-18 约翰霍普金斯大学 Treg耗尽和检查点抑制剂的组合
AU2019230230B2 (en) 2018-03-08 2025-04-10 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
KR20210076881A (ko) 2018-03-08 2021-06-24 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
WO2020028222A1 (en) 2018-07-29 2020-02-06 Musc Foundation For Research Development Compounds for the treatment of neurological or mitochondrial diseases
WO2020033130A1 (en) 2018-08-06 2020-02-13 The Johns Hopkins University Treatment of irritable bowel syndrome with molybdenum
US12103968B2 (en) 2018-08-16 2024-10-01 The Johns Hopkins University Antibodies to human ZnT8
WO2020163766A1 (en) 2019-02-07 2020-08-13 Baylor College Of Medicine Periosteal skeletal stem cells in bone repair
US11717506B2 (en) 2019-05-07 2023-08-08 The Johns Hopkins University Neuroprotective compounds for amyotrophic lateral sclerosis
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
EP3986931A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CA3144200A1 (en) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Compositions
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
JP7713447B2 (ja) 2019-11-27 2025-07-25 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための組み合わせ療法
EP4081227B1 (en) 2019-12-26 2026-04-01 SpinalCyte LLC Suppression of interleukin-17 production and inhibition of th17 cell generation by fibroblasts and products thereof
CA3164937A1 (en) 2019-12-26 2021-07-01 Figene, Llc Prevention and treatment of kidney failure by administration of fibroblasts and products thereof
KR20220163384A (ko) 2020-03-04 2022-12-09 플레오파마, 엘.엘.씨. 칸나비스 사용 장애를 치료하고 칸나비노이드 금단을 완화하기 위한 방법 및 조성물
US12098214B2 (en) 2021-05-13 2024-09-24 ALX Oncology Inc. Combination therapies for treating cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016254A (en) * 1972-05-19 1977-04-05 Beecham Group Limited Pharmaceutical formulations
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
LU76538A1 (es) * 1977-01-07 1978-09-18
US4469677A (en) * 1980-02-19 1984-09-04 Michael J Gabriel Polypeptide active immunosuppressant fraction
JPS5855125B2 (ja) * 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5230888A (en) * 1982-05-06 1993-07-27 Massachusetts Institute Of Technology Production of neutralizing antibodies by polypeptide VP1 of enteroviruses and by oligopeptide fragments of polypeptide VP1
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
DE3431861A1 (de) * 1984-08-30 1986-03-13 Troponwerke GmbH & Co KG, 5000 Köln Pellet-zubereitung
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0192321A3 (en) * 1985-01-19 1987-09-02 Beecham Group Plc Enteric coated allergen pharmaceutical composition
CH663900A5 (de) * 1985-05-06 1988-01-29 Cernitin Sa Pharmazeutisches praeparat zur prophylaktischen behandlung von allergien und verfahren zur herstellung dieses praeparates.
GB8519310D0 (en) * 1985-07-31 1985-09-04 Zyma Sa Granular active substances
US4820627A (en) * 1986-03-24 1989-04-11 Em Diagnostic Systems, Inc. Method of preparing particles suitable for tabletting into diagnostic reagents
JPH0759496B2 (ja) * 1986-03-25 1995-06-28 ロ−ト製薬株式会社 歯周病治療剤
US5019384A (en) * 1986-06-30 1991-05-28 Massachusetts Institute Of Technology Immunonodulating compositions and their use
DE3777658D1 (de) * 1986-08-28 1992-04-23 Enzacor Pty Ltd Tierwachstumserreger.
FR2609895B1 (fr) * 1987-01-28 1991-06-28 Bruttmann Georges Nouvelles formes galeniques d'allergenes pour administration par voie per- et sub-linguale
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPS6417A (en) * 1987-02-20 1989-01-05 Shikoku Chem Corp Chemotherapeutic agent composition
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4946945A (en) * 1987-06-23 1990-08-07 Allergy Immuno Technologies, Inc. Immunotherapy agents for treatment of IgE mediated allergies
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5049390A (en) * 1987-09-02 1991-09-17 Allergy Immuno Technologies, Inc. Liposome containing immunotherapy agents for treating IgE mediated allergies
IL87710A (en) * 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition
DE69001898T2 (de) * 1989-03-17 1993-09-23 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
CA2020654A1 (en) 1989-07-07 1991-01-08 Yohko Akiyama Stabilized fgf composition and production thereof
HUT69942A (en) * 1990-10-15 1995-09-28 Brigham & Womens Hospital Treatment of autoimmun diseases by oral administration of autoantigenes
JPH04230625A (ja) * 1990-12-27 1992-08-19 Standard Chem & Pharmaceut Corp Ltd 噴霧乾燥したジクロフェナクナトリウムを含み腸溶性の被覆を有するマイクロカプセルからなる微分散した錠剤組成物の製造方法
AU664561B2 (en) * 1991-06-21 1995-11-23 University Of Cincinnati, The Orally administrable therapeutic proteins and method of making
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
DK0603992T4 (da) * 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner

Also Published As

Publication number Publication date
EP0590060A1 (en) 1994-04-06
US5609871A (en) 1997-03-11
DE69222306D1 (de) 1997-10-23
US6174529B1 (en) 2001-01-16
CA2110899C (en) 2006-08-08
GR3025628T3 (en) 1998-03-31
WO1993000077A1 (en) 1993-01-07
DE69222306T2 (de) 1998-04-09
CA2110899A1 (en) 1993-01-07
AU664561B2 (en) 1995-11-23
US5629001A (en) 1997-05-13
EP0590060B1 (en) 1997-09-17
AU2249692A (en) 1993-01-25
JPH06508371A (ja) 1994-09-22
DK0590060T3 (da) 1998-05-11
EP0590060A4 (en) 1994-05-25
US5783193A (en) 1998-07-21
ATE158180T1 (de) 1997-10-15

Similar Documents

Publication Publication Date Title
ES2109362T3 (es) Unas proteinas administrables oralmente y metodo para hacerlas.
DK0603992T3 (da) Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner
ATE262348T1 (de) Mittel zur verabreichung von antigenen
DE69939747D1 (de) Verfahren von dna-impfung
ES453476A1 (es) Procedimiento para proporcionar una fuente de proteinas en forma concentrada.
NO882732D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
RU95106976A (ru) Композиции для оральной вакцинации жвачных, способы их изготовления и способы вакцинирования жвачных
NO995236D0 (no) Nerve-vekstfaktor som vaksine-adjuvant
JP2002326953A (ja) 経粘膜法により吸収されるワクチン
BG20584A3 (bg) Метод за получаване на n-<фурил-метил,порфинани и на техни присъединителни с киселинни соли
DK0421949T3 (da) Kemisk modificerede allergener og fremgangsmåde til deres fremstilling
RU93009804A (ru) Вакцина против эшерихиоза животных
MA20303A1 (fr) Composition nutritive contenant de l'acide alpha-cetoisocaproique, de la leucine et des acides amines essentiels et non essentiels.
GB2020665A (en) Acyl-N-acetylmuramylpeptide- antigen conjugate
DE3881698D1 (de) Lectine, die beta-d-galactosid binden.
RU2000104571A (ru) Способ коррекции иммунной недостаточности при желудочно-кишечных заболеваниях поросят
RU94031387A (ru) Способ повышения иммунного статуса цыплят путем сочетанного применения пробиотика и иммуномодулятора
RU97117569A (ru) Гастроветин
Tamaki et al. Genetic control of alkaline phosphatase isozymes in chicken duodenum
RU1808324C (ru) Способ профилактики и лечени казеинобезоарной болезни новорожденных гн т
O'Brien et al. Enterotoxic diseases due to Salmonella and Shigella.
EA199900044A1 (ru) Способ получения витаминного препарата и способ получения водорастворимого препарата
FR2148211A1 (en) Human milk substitute - prepd from whey and milk protein materials pptd at isoelectric point
TH3980B (th) แกรนูลขนาดจิ๋วที่เตรียมขึ้นซึ่งมีประโยชน์ในการนำส่งสารแสดงฤทธิ์ทางชีวภาพไปยังบริเวณลำไส้ของสัตว์
RU93056259A (ru) Средство для лечения диспепсии телят

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 590060

Country of ref document: ES